Author: Raturi, Manish; Kala, Mansi; Das, Kunal; Kusum, Anuradha
Title: Reviewing the Ethical Concerns of the Convalescent Plasma Therapy in COVID-19 Cord-id: bqf7rwqn Document date: 2021_4_24
ID: bqf7rwqn
Snippet: The understanding of coronavirus disease 2019 (COVID-19) is evolving periodically. There is also a marked increase in COVID-19 patients’ demand for the provision of COVID-19 convalescent plasma (CCP) therapy. With the review of the literature, the stage of speculation is quickly moving towards conformity, with the interim guidelines given by the Food and Drug Administration (FDA) in the United States, United Kingdom’s blood transfusion services, Saudi’s FDA, and the Indian Council for Medi
Document: The understanding of coronavirus disease 2019 (COVID-19) is evolving periodically. There is also a marked increase in COVID-19 patients’ demand for the provision of COVID-19 convalescent plasma (CCP) therapy. With the review of the literature, the stage of speculation is quickly moving towards conformity, with the interim guidelines given by the Food and Drug Administration (FDA) in the United States, United Kingdom’s blood transfusion services, Saudi’s FDA, and the Indian Council for Medical Research, in addition to the European health authorities. It is prudent to address the ethical concerns that merit consideration while harvesting and utilizing CCP as a therapeutic tool in local hospital setting.
Search related documents:
Co phrase search for related documents- adequate treatment and local regional: 1, 2
Co phrase search for related documents, hyperlinks ordered by date